Groundbreaking Findings on SKY92 Revolutionize Multiple Myeloma Risk Assessment and Treatment Planning SkylineDx reveals promising results from the PROMMIS study, confirming that SKY92 gene profiling improves risk stratification in multiple myeloma patients, enhancing treatment decisions and patient care.

Groundbreaking Findings on SKY92 Revolutionize Multiple Myeloma Risk Assessment and Treatment Planning #United_States #San_Diego #Multiple_Myeloma #SkylineDx #SKY92

SkylineDx's Groundbreaking Research on SKY92 Gene Test Supports Ultra-High-Risk Multiple Myeloma Identification SkylineDx announces a pivotal study on the SKY92 gene expression test, enhancing multiple myeloma patient risk identification for improved treatment.

SkylineDx's Groundbreaking Research on SKY92 Gene Test Supports Ultra-High-Risk Multiple Myeloma Identification #Netherlands #Multiple_Myeloma #Rotterdam #SkylineDx #SKY92

New PROMMIS Study Reports Breakthrough in Identifying High-Risk Multiple Myeloma Patients with SKY92 Recent findings from the PROMMIS study reveal that the SKY92 gene expression profiling classifier significantly improves the identification of high-risk multiple myeloma patients, aiding in better treatment strategies.

New PROMMIS Study Reports Breakthrough in Identifying High-Risk Multiple Myeloma Patients with SKY92 #Netherlands #Multiple_Myeloma #Rotterdam #SkylineDx #SKY92